Summary

The is a first clinical study for Oricell Therapeutics Inc. in the United States to
evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product
(OriCAR-017) in subjects with relapsed/refractory multiple myeloma.

RIGEL Study

Objectives

This is a Phase I/II, open-label multicenter study to evaluate the safety,
pharmacokinetics, pharmacodynamics, and preliminary efficacy of anti-GPRC5D CAR-T cell
product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma". The study
will consist of a Phase I dose escalation stage involving three doses as a single IV
infusion) with up to 18 evaluable subjects and a dose expansion stage with 10-15
evaluable subjects, followed by a Phase II stage with up to 48 evaluable subjects.